Evelo Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	2017 - 2016
Net Income	-82.35	-114.53	-122.18	-93.67	-85.66	-53.85	Upgrade
Depreciation & Amortization	1.56	2.06	2.22	2.03	1.76	1.94	Upgrade
Share-Based Compensation	11.17	15.16	15.85	8.47	8.17	0	Upgrade
Other Operating Activities	-4.08	-3.93	7.39	10.11	3.75	4.64	Upgrade
Operating Cash Flow	-73.7	-101.24	-96.73	-73.06	-71.98	-47.28	Upgrade
Capital Expenditures	-0.29	-0.62	-1.52	-1.32	-3.03	-5.46	Upgrade
Change in Investments	-	-	-	-	-55	-217.34	Upgrade
Other Investing Activities	0.55	-	0.04	0.01	110	162.67	Upgrade
Investing Cash Flow	0.26	-0.62	-1.48	-1.32	51.97	-60.13	Upgrade
Common Stock Issued	28.93	84.54	81.75	54.99	0	75.83	Upgrade
Other Financing Activities	-8.37	-2.89	15.79	10.47	4.99	86.18	Upgrade
Financing Cash Flow	20.56	81.66	97.54	65.47	4.99	162.01	Upgrade
Net Cash Flow	-52.15	-20.66	-0.67	-8.91	-15.02	54.61	Upgrade
Free Cash Flow	-73.99	-101.86	-98.24	-74.38	-75.01	-52.74	Upgrade
Free Cash Flow Per Share	-4.26	-23.37	-37.14	-37.68	-46.84	-48.23	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.